VANCOUVER, British Columbia, & SEATTLE, Wash.–(BUSINESS WIRE)–Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) has entered into a Term Sheet with SōRSE Technology (“SōRSE”) to develop Pascal’s cannabinoid programs. Investing in and financially supporting Pascal Biosciences’ research marks the first step for SōRSE Technology moving into medical research applications. This partnership leverages SōRSE’s industry-leading formulation technology with Pascal’s cannabinoid programs for clinical trials,

READ MORE: https://www.businesswire.com/news/home/20200311005207/en/S%C5%8DRSE-Technology-Partners-Acquires-Part-Cancer-Research/?feedref=JjAwJuNHiystnCoBq_hl-W8j9Oi60kFTomUxRDB8jhB8bDel5XZmwWFQYQPHxx__rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3kCXJZE-1b1nXn968wYfofVLkaZDLiczsahzEklD3R10Q==